This is a preview of subscription content, log in via an institution to check access.
Reference
Wymer KM, et al. Cost-Effectiveness Analysis of Pembrolizumab for BCG-Unresponsive Carcinoma in Situ of the Bladder. Journal of Urology : 101097JU0000000000001515, 21 Dec 2020. Available from: URL: http://doi.org/10.1097/JU.0000000000001515
Rights and permissions
About this article
Cite this article
Pembrolizumab not cost effective in BCG-unresponsive bladder carcinoma in situ. PharmacoEcon Outcomes News 869, 24 (2021). https://doi.org/10.1007/s40274-021-7391-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7391-y